What is the primary driver behind the significant year-over-year revenue decrease reported in the second quarter and first half of 2022?

The substantial decrease in total revenues is primarily due to the absence of REGEN-COV sales. REGEN-COV sales were a significant revenue driver in the comparable periods of 2021, but the company has completed its deliveries under agreements with the U.S. government, and the drug's effectiveness against Omicron variants led to a revision of its Emergency Use Authorization, rendering it not authorized for use in most U.S. states.

How are Regeneron's key products, EYLEA and Dupixent, performing?

Both EYLEA and Dupixent demonstrated strong performance with significant year-over-year growth in net product sales for both the three-month and six-month periods ended June 30, 2022. EYLEA sales increased by 9% and 10% respectively, while Dupixent sales saw robust growth of 40% and 41% respectively, indicating continued market demand and successful commercialization.

What are the key strategic developments that occurred during the reporting period?

Regeneron made two significant strategic moves. First, they acquired Checkmate Pharmaceuticals for approximately $250 million, adding vidutolimod, an immuno-oncology candidate, to their pipeline. Second, they amended their Immuno-oncology collaboration with Sanofi, securing exclusive worldwide rights to Libtayo for an upfront payment of $900 million, plus potential regulatory and sales milestones and royalties. These moves strengthen Regeneron's oncology franchise and commercial control over a key product.

What is the company's cash position and capital allocation strategy?

Regeneron maintains a strong liquidity position with cash and cash equivalents of $3,395.1 million and marketable securities of $10,587.2 million as of June 30, 2022. The company also reported strong operating cash flow generation. Additionally, Regeneron continues to actively execute its share repurchase program, with $2.099 billion remaining available under its $3.0 billion authorization as of the end of the second quarter.

REGN 10-Q Quarterly Report Q2 FY2022 — Revenue, Net Income, EPS

Summary

Regeneron Pharmaceuticals, Inc. reported its financial results for the second quarter and first half of 2022. The company saw a significant decrease in total revenues for both the three and six-month periods compared to the prior year, primarily driven by the absence of REGEN-COV sales, which were substantial in the first half of 2021. Despite the revenue decline, Regeneron demonstrated strong operational cash flow generation. Key product sales, particularly for EYLEA and Dupixent, showed robust year-over-year growth, indicating continued strong demand for these core products. The company also made significant strategic moves, including the acquisition of Checkmate Pharmaceuticals, which added an oncology pipeline asset, and an amendment to its Immuno-oncology collaboration with Sanofi, granting Regeneron exclusive worldwide rights to Libtayo. These strategic actions, coupled with a strong cash position and an ongoing share repurchase program, position Regeneron for future growth despite near-term revenue headwinds from the REGEN-COV wind-down.

Financial Highlights

45 data points

Beta

Revenue

$2.86B

Net Income

$852.10M

0.3% Net Margin

EPS (Diluted)

$7.47

Total Assets

$27.21B

Cash & Equivalents

$3.40B

Free Cash Flow

$564.40M

Financial Statements

Beta

Revenue	$2.86B
R&D Expenses	$794.30M
SG&A Expenses	$476.30M
Operating Expenses	$1.75B
Operating Income	$1.11B
Interest Expense	$13.10M
Net Income	$852.10M
EPS (Basic)	$7.90
EPS (Diluted)	$7.47
Shares Outstanding (Basic)	107.90M
Shares Outstanding (Diluted)	114.00M

Key Highlights

1Total revenues decreased by 44% for the three months ended June 30, 2022, and by 24% for the six months ended June 30, 2022, primarily due to the cessation of REGEN-COV sales.
2Net product sales for EYLEA increased by 9% to $2,491.0 million for the three months ended June 30, 2022, and by 10% to $4,877.1 million for the six months ended June 30, 2022.
3Net product sales for Dupixent increased by 40% to $2,091.8 million for the three months ended June 30, 2022, and by 41% to $3,902.2 million for the six months ended June 30, 2022.
4The company acquired Checkmate Pharmaceuticals for approximately $250 million, adding vidutolimod for oncology development.
5Effective July 1, 2022, Regeneron obtained exclusive worldwide rights to Libtayo from Sanofi for an upfront payment of $900 million, royalty payments, and milestone payments.
6Net cash provided by operating activities was $2,666.1 million for the six months ended June 30, 2022, a significant increase from $1,295.2 million in the prior year period.
7As of June 30, 2022, Regeneron had $2.099 billion remaining under its authorized share repurchase program.

REGENERON PHARMACEUTICALS, INC. Quarterly Report for Q2 Ended Jun 30, 2022

Summary

Financial Highlights

Key Highlights

Frequently Asked Questions